| Date | Title | Description |
| 18.08.2026 | OssDsign AB (publ) publishes Q2 2026 interim report | OssDsign AB (publ) publishes Q2 2026 interim report
Tue, Aug 18, 2026 07:00 CET Report this content
Progress: Building the foundation for OssDsign growth
OssDsign AB (publ) announces that the interim report for Q2 2026 is now available as a... |
| 25.06.2026 | OssDsign appoints Adam McCollister as new Vice President of Sales | OssDsign appoints Adam McCollister as new Vice President of Sales
Thu, Jun 25, 2026 17:30 CET Report this content
OssDsign Appoints Adam McCollister as Vice President of Sales to Accelerate U.S. Growth of Catalyst Platform
Uppsala, Sweden, ... |
| 11.05.2026 | Notice to attend the Annual General Meeting in OSSDSIGN AB | Notice to attend the Annual General Meeting in OSSDSIGN AB
Mon, May 11, 2026 16:00 CET Report this content
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 am on Tu... |
| 05.05.2026 | OssDsign AB (publ) publishes Q1 2026 interim report | OssDsign AB (publ) publishes Q1 2026 interim report
Tue, May 05, 2026 07:00 CET Report this content
Reset: Laying the groundwork for accelerated growth
OssDsign AB (publ) announces that the interim report for Q1 2026 is now available as a P... |
| 10.04.2026 | OssDsign provides pre-release update on Q1 2026 performance | OssDsign provides pre-release update on Q1 2026 performance
Fri, Apr 10, 2026 14:00 CET Report this content
OssDsign AB (publ.) today announces that preliminary revenue for the period January – March, 2026 will be USD 4.035 million or SEK 3... |
| 03.02.2026 | OssDsign AB (publ) publishes year-end report 2025 | OssDsign AB (publ) publishes year-end report 2025
Tue, Feb 03, 2026 07:00 CET Report this content
Strong growth and real-world data set the stage for U.S. market expansion
OssDsign AB (publ) announces that the year-end report for 2025 is no... |
| 10.12.2025 | OssDsign appoints Mark Waugh as new CEO | OssDsign appoints Mark Waugh as new CEO
Wed, Dec 10, 2025 08:00 CET Report this content
Uppsala, Sweden, 10th December, 2025 - OssDsign AB (publ.) today announces the appointment of Mark Waugh as CEO, effective 1st January 2026. He most rec... |
| 04.11.2025 | OssDsign AB (publ) publishes Q3 2025 interim report | OssDsign AB (publ) publishes Q3 2025 interim report
Tue, Nov 04, 2025 07:00 CET Report this content
Record breaking sales month and best quarterly EBIT result
OssDsign AB (publ) announces that the interim report for Q3 2025 is now available... |
| 02.09.2025 | Performance of OssDsign Catalyst® in a patient with post-traumatic ankle arthritis showcased in medical journal | Performance of OssDsign Catalyst® in a patient with post-traumatic ankle arthritis showcased in medical journal
Tue, Sep 02, 2025 10:14 CET Report this content
Uppsala, Sweden, September 2, 2025. OssDsign AB (publ.) today announces that a c... |
| 19.08.2025 | OssDsign AB (publ) publishes Q2 2025 interim report | OssDsign AB (publ) publishes Q2 2025 interim report
Tue, Aug 19, 2025 07:00 CET Report this content
Extraordinary real-world clinical data and strengthened balance sheet to launch new "ScaleToProfit” growth strategy
OssDsign AB (publ) ... |
| 01.07.2025 | Breakthrough in Spinal Fusion: OssDsign's Catalyst Shows Promising Results | In the realm of spinal surgery, success often hinges on the delicate balance between innovation and patient complexity. OssDsign AB has recently unveiled compelling data from its PROPEL registry, showcasing a remarkable 88.4% fusion rate am... |
| 01.07.2025 | OssDsign's Catalyst: A Game Changer in Spinal Fusion Surgery | In the world of spinal surgery, the stakes are high. Patients often face complex challenges. Failed surgeries, high body mass indexes, and multiple health issues complicate the landscape. Yet, a beacon of hope has emerged. OssDsign AB has u... |
| 01.07.2025 | Exercise period starts in OssDsign’s long-term incentive warrant program 2022/2025, boosting the company’s cash position by up to SEK 10 million | Exercise period starts in OssDsign’s long-term incentive warrant program 2022/2025, boosting the company’s cash position by up to SEK 10 million
Tue, Jul 01, 2025 09:02 CET Report this content
Uppsala, July 1, 2025. OssDsign AB (publ.) anno... |
| 26.06.2025 | OssDsign announces remarkable real-world results with 88.4% fusion rate in a highly complex patient cohort from the spinal fusion registry PROPEL | OssDsign announces remarkable real-world results with 88.4% fusion rate in a highly complex patient cohort from the spinal fusion registry PROPEL
Thu, Jun 26, 2025 15:09 CET Report this content
Uppsala, June 26, 2025. OssDsign AB (publ.) to... |
| 12.06.2025 | The Pulse of Corporate Governance: Insights from Recent Annual General Meetings | In the world of corporate governance, the Annual General Meeting (AGM) serves as a vital heartbeat. It’s where shareholders gather to make decisions that shape the future of their companies. Recently, two AGMs stood out: China Yuchai Intern... |
| 11.06.2025 | Annual General Meeting held in OssDsign AB | Annual General Meeting held in OssDsign AB
Wed, Jun 11, 2025 14:00 CET Report this content
11 June 2025. Today, the annual general meeting of 2025 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual ge... |
| 09.06.2025 | Revised proposal for election of the board of directors in OssDsign | Revised proposal for election of the board of directors in OssDsign
Mon, Jun 09, 2025 14:00 CET Report this content
Uppsala, June 9, 2025. OssDsign AB (publ.) today announces, through the nomination committee, a revised proposal for electio... |
| 04.06.2025 | OssDsign's Bold Move: A Strategic Share Issue to Fuel Growth | OssDsign AB, a prominent player in the orthobiologics market, has made headlines with its recent directed share issue. On June 3, 2025, the company announced the completion of a share issue that raised approximately SEK 158 million. This st... |
| 03.06.2025 | OssDsign has carried out a directed share issue of approximately SEK 158 million | OssDsign has carried out a directed share issue of approximately SEK 158 million
Tue, Jun 03, 2025 23:04 CET Report this content
June 3, 2025, 23:04 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue... |
| 03.06.2025 | OssDsign explores the conditions for increasing the scope of the directed share issue to approximately 11.5 million shares | OssDsign explores the conditions for increasing the scope of the directed share issue to approximately 11.5 million shares
Tue, Jun 03, 2025 19:35 CET Report this content
June 3, 2025, 19:35 CEST. OssDsign AB (publ) (”OssDsign” or the ”Comp... |
| 14.05.2025 | OssDsign included in MSCI index | OssDsign included in MSCI index
Wed, May 14, 2025 15:00 CET Report this content
Uppsala, May 14, 2025. Today, OssDsign AB (publ.) today announces that the company’s share will be included in the MSCI Global Micro Cap Index, implemented as o... |
| 14.05.2025 | OssDsign publishes Annual Report 2024 | OssDsign publishes Annual Report 2024
Wed, May 14, 2025 07:00 CET Report this content
OssDsign AB (publ) announces that the Annual Report for 2024 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also a... |
| 13.05.2025 | Ambea and OssDsign: A Tale of Growth and Innovation in Healthcare | In the ever-evolving landscape of healthcare, two companies stand out: Ambea and OssDsign. Both are making waves, but in different ways. Ambea is deepening its roots in the care sector, while OssDsign is revolutionizing orthobiologics. Thei... |
| 12.05.2025 | 10,000 patients treated with OssDsign Catalyst® in the U.S. | 10,000 patients treated with OssDsign Catalyst® in the U.S.
Mon, May 12, 2025 16:02 CET Report this content
Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with the in... |
| 07.05.2025 | Resilience in Real Estate and Innovation in Healthcare: A Look at Q1 2025 Results | The first quarter of 2025 paints a vivid picture of two companies navigating their respective landscapes: Heimstaden AB in real estate and OssDsign AB in healthcare. Both firms showcase resilience, innovation, and a commitment to growth, de... |
| 06.05.2025 | OssDsign AB (publ) publishes Q1 2025 interim report | OssDsign AB (publ) publishes Q1 2025 interim report
Tue, May 06, 2025 07:00 CET Report this content
Strong growth and best operating result ever
OssDsign AB (publ) announces that the interim report for Q1 2025 is now available as a PDF on t... |
| 30.04.2025 | OssDsign announces CEO transition planned for the second half of 2025 | OssDsign announces CEO transition planned for the second half of 2025
Wed, Apr 30, 2025 07:00 CET Report this content
Uppsala, April 30, 2025. OssDsign® AB (publ.) today announces that Morten Henneveld will step down as CEO at the end of th... |
| 12.04.2025 | Revolutionizing Bone Healing: The Breakthrough of OssDsign Catalyst | In the world of medicine, breakthroughs often emerge from the shadows of traditional practices. A recent study has illuminated a path forward in bone graft technology. The focus? OssDsign Catalyst, a synthetic bone graft that is changing th... |
| 12.04.2025 | The Future of Healing: A Leap in Synthetic Bone Grafts | In the realm of medical innovation, breakthroughs often resemble the first rays of dawn breaking through a dark night. Recently, OssDsign® AB has illuminated the path forward with its groundbreaking study on synthetic bone grafts. This rese... |
| 11.04.2025 | Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts | Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts
Fri, Apr 11, 2025 14:31 CET Report this content
Uppsala, April 11, 2025. OssDsign® AB (publ.) today announces that a new preclinica... |
| 09.04.2025 | 24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion | 24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion
Wed, Apr 09, 2025 10:41 CET Report this content
Uppsala, April 9, 2025. OssDsign AB (publ.) today announces that the 24-month follow up results fr... |
| 01.03.2025 | OssDsign and SciBase: Pioneering Advances in Medical Technology | In the world of medical technology, innovation is the lifeblood that fuels progress. Two companies, OssDsign and SciBase, are making waves with their recent developments. Both are focused on enhancing patient outcomes through advanced produ... |
| 25.02.2025 | OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL | OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL
Tue, Feb 25, 2025 07:00 CET Report this content
Uppsala, February 25, 2025. OssDsign AB (publ.) today announced that the company has reach... |
| 04.02.2025 | OssDsign AB (publ) publishes year-end report 2024 | OssDsign AB (publ) publishes year-end report 2024
Tue, Feb 04, 2025 07:00 CET Report this content
Strategic transformation completed with proven scalability
OssDsign AB (publ) announces that the year-end report for 2024 is now available as ... |
| 18.12.2024 | Extraordinary General Meeting held in OssDsign AB | Extraordinary General Meeting held in OssDsign AB
Wed, Dec 18, 2024 11:10 CET Report this content
Today, an extraordinary general meeting was held in OssDsign AB (publ). Below is a summary of the resolutions adopted at the extraordinary gen... |
| 29.11.2024 | Notice to attend the extraordinary general meeting in OssDsign AB | Notice to attend the extraordinary general meeting in OssDsign AB
Fri, Nov 29, 2024 07:00 CET Report this content
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the extraordinary general meeting at ... |
| 12.11.2024 | OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin | OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin
Tue, Nov 12, 2024 07:00 CET Report this content
OssDsign AB (publ) announces that the interim report for Q3 2024 is now available as a PDF on the compan... |
| 02.10.2024 | OssDsign has appointed Stephen Anderson as Vice President of Marketing | OssDsign has appointed Stephen Anderson as Vice President of Marketing
Wed, Oct 02, 2024 09:00 CET Report this content
OssDsign AB (publ.) today announced that the company has appointed Stephen Anderson as Vice President (VP) of Marketing a... |
| 20.08.2024 | OssDsign AB (publ) publishes Q2 2024 Interim Report | OssDsign AB (publ) publishes Q2 2024 Interim Report
Tue, Aug 20, 2024 07:00 CET Report this content
Reaching milestone in orthobiologics sales
OssDsign AB (publ) announces that the interim report for Q2 2024 is now available as a PDF on the... |
| 25.06.2024 | Annual General Meeting held in OssDsign AB | Annual General Meeting held in OssDsign AB
Tue, Jun 25, 2024 15:00 CET Report this content
Today, the annual general meeting of 2024 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting ... |
| 24.06.2024 | Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign | Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign
Mon, Jun 24, 2024 14:00 CET Report this content
The board of directors of OssDsign AB, following discussions with a larger... |
| 04.06.2024 | OssDsign publishes Annual Report 2023 | OssDsign publishes Annual Report 2023
Tue, Jun 04, 2024 08:00 CET Report this content
OssDsign AB (publ) announces that the Annual Report for 2023 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also a... |
| 30.05.2024 | 5,000 patients treated with OssDsign Catalyst® in the U.S. | 5,000 patients treated with OssDsign Catalyst® in the U.S.
Thu, May 30, 2024 12:28 CET Report this content
Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobi... |
| 24.05.2024 | NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB | NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB
Fri, May 24, 2024 14:22 CET Report this content
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 am on Tu... |
| 16.05.2024 | Change of financial calendar | Change of financial calendar
Thu, May 16, 2024 09:28 CET Report this content
Adjusting to other dates in the company’s financial calendar, OssDsign has decided to change the annual report release date to June 4, 2024. Previously communicate... |
| 14.05.2024 | OssDsign AB (publ) publishes Q1 2024 interim report | OssDsign AB (publ) publishes Q1 2024 interim report
Tue, May 14, 2024 07:00 CET Report this content
We have successfully entered a new era as a pure play orthobiologics company
OssDsign AB (publ) announces that the interim report for Q1 202... |
| 29.04.2024 | OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals | OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals
Mon, Apr 29, 2024 09:43 CET Report this content
Uppsala, Sweden, April 29 – OssDsign AB (publ.) today announces that the company has been awa... |
| 02.04.2024 | OssDsign awarded long-term agreement with Premier, Inc. | OssDsign awarded long-term agreement with Premier, Inc.
Tue, Apr 02, 2024 07:00 CET Report this content
Uppsala, Sweden, April 2 – OssDsign AB (publ.) today announces that the company has been awarded a new group purchasing (GPO) agreement ... |
| 06.02.2024 | OssDsign AB (publ) publishes year-end report 2023 | OssDsign AB (publ) publishes year-end report 2023
Tue, Feb 06, 2024 07:00 CET Report this content
Exceptional sales growth for OssDsign Catalyst confirms the value of our strategy shift
OssDsign AB (publ) announces that the interim report f... |
| 21.11.2023 | OssDsign AB (publ) publishes Q3 2023 Interim Report | OssDsign AB (publ) publishes Q3 2023 Interim Report
Tue, Nov 21, 2023 08:00 CET Report this content
A new era with OssDsign as a pure play orthobiologics company
OssDsign AB (publ) announces that the interim report for Q3 2023 is now availa... |
| 16.10.2023 | Extraordinary General Meeting held in OssDsign AB | Extraordinary General Meeting held in OssDsign AB
Mon, Oct 16, 2023 11:00 CET Report this content
Today an extraordinary general meeting was held in OssDsign AB (publ) (the “Company”). Below is a summary of the resolutions passed at the gen... |
| 18.09.2023 | OssDsign® Catalyst receives clearance from FDA for major new indication for use in interbody cages | OssDsign® Catalyst receives clearance from FDA for major new indication for use in interbody cages
Mon, Sep 18, 2023 08:00 CET Report this content
Uppsala, Sweden, September 18, 2023. OssDsign AB (publ.) today announces that the company’s i... |
| 22.08.2023 | OssDsign AB (publ) publishes Q2 2023 Interim Report | OssDsign AB (publ) publishes Q2 2023 Interim Report
Tue, Aug 22, 2023 08:00 CET Report this content
Bone graft now the biggest franchise.
OssDsign AB (publ) announces that the interim report for Q2 2023 is now available as a PDF on the comp... |
| 16.08.2023 | OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL | OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL
Wed, Aug 16, 2023 09:00 CET Report this content
Uppsala, August 16, 2023. OssDsign AB (publ.) today announces that the company has enrolled 200 patients in the... |
| 31.05.2023 | Annual General Meeting held in OssDsign AB | Annual General Meeting held in OssDsign AB
Wed, May 31, 2023 13:30 CET Report this content
Today, the annual general meeting of 2023 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting ... |
| 23.05.2023 | OssDsign AB (publ) publishes Q1 2023 Interim Report | OssDsign AB (publ) publishes Q1 2023 Interim Report
Tue, May 23, 2023 08:00 CET Report this content
Sustainable and accelerating growth
OssDsign AB (publ) announces that the interim report for Q1 2023 is now available as a PDF on the compan... |
| 09.05.2023 | 1,000 patients treated with OssDsign® Catalyst in the U.S. | 1,000 patients treated with OssDsign® Catalyst in the U.S.
Tue, May 09, 2023 12:37 CET Report this content
Uppsala, May 9, 2023. OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with the innovative nanos... |
| 27.04.2023 | OssDsign publishes Annual Report 2022 | OssDsign publishes Annual Report 2022
Thu, Apr 27, 2023 09:00 CET Report this content
OssDsign AB (publ) announces that the Annual Report for 2022 is now available as a PDF on the company's website www.ossdsign.com. A PDF version is also at... |
| 27.04.2023 | OssDsign reaches commercial milestone of 750 implants sold in Germany | OssDsign reaches commercial milestone of 750 implants sold in Germany
Thu, Apr 27, 2023 08:00 CET Report this content
Uppsala, April 27, 2023. OssDsign AB (publ.) today announces that the company has reached the commercial milestone of 750 ... |
| 20.03.2023 | OssDsign increases operational efficiency and reduces Cranial PSI lead time by up to 40 percent | OssDsign increases operational efficiency and reduces Cranial PSI lead time by up to 40 percent
Mon, Mar 20, 2023 08:00 CET Report this content
Uppsala, 20 March 2023. OssDsign AB (publ.) announces today that the company has significantly r... |
| 14.03.2023 | OssDsign reaches commercial milestone of 200 implants in France | OssDsign reaches commercial milestone of 200 implants in France
Tue, Mar 14, 2023 08:00 CET Report this content
Uppsala, March 14 2023. OssDsign AB (publ.) today announces that the company has reached the commercial milestone of 200 implant... |
| 21.02.2023 | OssDsign AB (publ) publishes Year-end Report 2022 | OssDsign AB (publ) publishes Year-end Report 2022
Tue, Feb 21, 2023 08:00 CET Report this content
A year of sustained high growth and demonstrated scalability
The fourth quarter in figures
Net sales amounted to TSEK 19,929 (9,174)
Loss afte... |
| 10.01.2023 | OssDsign Catalyst 1cc is now launched and available in the U.S. market | OssDsign Catalyst 1cc is now launched and available in the U.S. market
Tue, Jan 10, 2023 14:14 CET Report this content
Uppsala, 10 January 2023. OssDsign AB (publ.) announces today that the company has now commenced the launch of a new size... |
| 09.01.2023 | OssDsign reaches milestone of 500 patients treated with OssDsign® Catalyst in the U.S. | OssDsign reaches milestone of 500 patients treated with OssDsign® Catalyst in the U.S.
Mon, Jan 09, 2023 08:00 CET Report this content
Uppsala, January 9, 2023. OssDsign AB (publ.) today announces that 500 patients have now been treated in ... |
| 04.01.2023 | First-in-patient case report of OssDsign Catalyst shows complete spinal fusion 6 months post-surgery | First-in-patient case report of OssDsign Catalyst shows complete spinal fusion 6 months post-surgery
Wed, Jan 04, 2023 08:00 CET Report this content
Uppsala, January 4, 2023. OssDsign AB (publ.) today announces that a first-in-patient case ... |
| 29.11.2022 | OssDsign AB completes a directed new share issue raising proceeds of approximately SEK 65.6 million | OssDsign AB completes a directed new share issue raising proceeds of approximately SEK 65.6 million
Tue, Nov 29, 2022 22:46 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN... |
| 21.06.2022 | OssDsign launches Cranial PSI in Japan and records first sales | OssDsign launches Cranial PSI in Japan and records first sales
Tue, Jun 21, 2022 11:00 CET Report this content
Uppsala, June 21, 2022. OssDsign AB (publ.) today announces that the company has completed its first sales of OssDsign Cranial PS... |
| 13.06.2022 | The first 100 patients in the U.S. treated with OssDsign Catalyst | The first 100 patients in the U.S. treated with OssDsign Catalyst
Mon, Jun 13, 2022 12:00 CET Report this content
Uppsala, June 13, 2022. OssDsign AB (publ.) today announces that the first 100 patients in the U.S. have now been treated with... |
| 08.06.2022 | OssDsign announces that SEB has initiated research coverage of the company | OssDsign announces that SEB has initiated research coverage of the company
Wed, Jun 08, 2022 09:00 CET Report this content
Uppsala, June 8, 2022. OssDsign AB (publ.) today announces that Skandinaviska Enskilda Banken (publ) (SEB) has been e... |
| 07.06.2022 | OssDsign announces the establishment of a U.S. Strategic Surgeon Advisory Board | OssDsign announces the establishment of a U.S. Strategic Surgeon Advisory Board
Tue, Jun 07, 2022 09:58 CET Report this content
Uppsala, June 7, 2022. OssDsign AB (publ.) today announces that the company has established a Strategic Surgeon ... |
| 01.06.2022 | Annual General Meeting held in OssDsign AB | Annual General Meeting held in OssDsign AB
Wed, Jun 01, 2022 12:00 CET Report this content
Today, the annual general meeting of 2022 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting ... |
| 22.03.2022 | OssDsign signs long-term contract with the largest hospital network in France to deliver unique patient specific cranial technology | OssDsign signs long-term contract with the largest hospital network in France to deliver unique patient specific cranial technology
Tue, Mar 22, 2022 11:00 CET Report this content
Uppsala, March 22, 2022. OssDsign AB (publ.) today announces... |
| 18.08.2021 | OssDsign AB (publ) publishes Q2 2021 Interim Report | OssDsign AB (publ) publishes Q2 2021 Interim Report Wed, Aug 18, 2021 08:00 CET
Continued sales growth despite ongoing COVID-19 pandemic
The second quarter in figures
Net sales amounted to TSEK 7,643 (3,905)
Loss after taxes amounted to TSE... |
| 21.05.2021 | Notice to attend the Annual General Meeting in OssDsign AB | Notice to attend the Annual General Meeting in OssDsign AB Fri, May 21, 2021 17:00 CET
The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Tuesday 22 June 2021... |
| 21.05.2021 | OssDsign : Notice to attend the Annual General Meeting in OssDsign AB | The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Tuesday 22 June 2021. The meeting will be held through postal voting only (see below).
Special arrangements... |
| 12.05.2021 | KAROLINSKA DEVELOPMENT AB (PUBL)
Karolinska Development : portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue | STOCKHOLM, SWEDEN – May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential rights for the company's existing share... |
| 12.05.2021 | OSSDSIGN AB (PUBL)
OssDsign : raises SEK 270 million in oversubscribed rights issue and utilised over-allotment option | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AMERICA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE REL... |
| 12.05.2021 | Karolinska Development : portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue | STOCKHOLM, SWEDEN – May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential rights for the company's existing share... |
| 12.01.2016 | Nordic tech in Q4: the most active quarter so far | In Q4, tech startups based in Nordic countries collectively raised $309.8 million in 107 rounds. Though not the biggest quarter of 2015 in terms of amount raised – a distinction still carried by Q2 and its massive $812.8 million cumulative ... |
| 04.11.2015 | OssDsign Raises €9.6M in Equity Financing | OssDsign AB, an Uppsala, Sweden-based medtech company, raised SEK93m (€9.6m) in equity financing.
The round was led by new investors SEB Venture Capital and Fouriertransform with continued investment from Karolinska Development.
The company... |
| 04.11.2015 | Daily funding roundup - November 4, 2015 | Atreca completed $56M funding; Zhihu raised $50M; The History Project launched with $2M funding
The History Project, an Oakland, CA-based platform that allows users to take control of digital and physical assets and build them into shareabl... |
